

FORM 7

MARCH 2020 MONTHLY PROGRESS REPORT

Name of Listed Issuer: **RIWI Corp.** (the "Issuer")

Trading Symbol: RIW

Number of Outstanding Listed Securities: **17,934,428 common shares**

Date: April 6, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 Interpretation and General Provisions.



Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

To grow recurring revenues, RIWI completed the following activities:

- (a) Further to the Company's News Release of March 26, 2020, RIWI signed an agreement with ThinkData Works Inc. ("ThinkData"), a data access solution company, to service a *Fortune 500* healthcare client, which needs RIWI data in 16 countries facing challenges posed by COVID-19. RIWI's work under this first agreement with ThinkData is valued at US \$1,037,200 and will be completed over six months. ThinkData enjoys the right to renew and increase the duration and value of the agreement. ThinkData can expand the contract's scope to cover all countries and health systems in the world.
- (b) The Company signed a new contract with a Washington, DC-based international consulting firm, a new client, for RIWI data collection services in North Africa.
- (c) RIWI's product and customer success teams continued servicing our clients around the world in the technology, University, and financial services sectors.
- (d) RIWI management continued its work and responded to solicited requests for proposals on behalf of private and non-profit clients funded by G7 agencies, including the US Department of State and other branches of the US government.
- (e) Further to the CEO's Annual Letter to Shareholders (of March 25, 2020), RIWI announced that it has secured more than US \$2.5 million in recurring revenue business so far this year. The CEO's Annual Letter noted that RIWI continues to serve clients such as the US Department of State, G7 agencies mandated to keep the world safe, BofA securities, the UN World Food Programme, Harvard University, the US Agency for International Aid and Development, and one central bank.
- (f) In order to accelerate the Company's goals to increase international sales and marketing, management is recruiting and hiring for several new full-time positions.



2. Provide a general overview and discussion of the activities of management.

- (a) To build market awareness and sales, RIWI continued to capture time-series data to document economic resilience, consumer sentiment, physical distancing trends, and health system stability globally, including in China, amid the COVID-19 pandemic.
- (b) RIWI management prepared sales proposals relating to COVID-19 data collection for a wide range of University-based, government-funded and private-sector firms requesting RIWI's data analytics services to support rapid-response data collection.
- (c) On March 26, 2020, RIWI's Founder and Chief Executive Officer led a webinar to an international audience of public health researchers, businesses and the public, hosted by the Dalla Lana School of Public Health at the University of Toronto, and by the North American Observatory on Health Systems and Policies. In response to concerns about COVID-19, RIWI's CEO continues to prepare for webinars on RIWI technologies and data, upon the invitation of US and international policy-makers.
- (d) Management has prepared and disseminated marketing material to clients and prospective clients describing the firm's differentiated data offerings to assist firms and government agencies prepare, adapt and respond to the COVID-19 pandemic.
- (e) Management has struck strategic alignments with other data firms for the purposes of sales efforts dedicated to expanding RIWI's work in public health security.
- (f) On March 11, 2020, Reformulary Group, a healthcare company, released a study based on RIWI's data that demonstrated the importance of a medical cannabis rating system and the need for greater information about the composition of each product as well as the therapeutic value of various medical cannabis.
- (g) To build market awareness and sales, RIWI continues to track regional and other US voter trends in order to publicly predict the outcome of the 2020 US Presidential election, including how the government's response to COVID-19 is affecting these voting predictions. RIWI provides relevant data for the media and for the public.
- (h) To build market awareness and sales, RIWI continues to work with two major media firms and with research units at 11 Universities in the United States and Canada in order to collect data about the causes of certain public health risks.
- (i) To build market awareness and sales, RIWI promoted publications that featured the Company's technology and RIWI data. Most recently, these included: RIWI's economic data for BofA Securities, referenced in *The Daily Telegraph*; a paper by University-based researchers for the Society for the Study of Economic Inequality (ECINEQ) and funded by Oxfam, a RIWI client; and a study on Chinese vs. US confidence in COVID-19 response measures, authored by Gary Clyde Hufbauer, an economist based at The Peterson Institute for International Economics.



3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

RIWI expands capabilities of existing products following regular customer feedback.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

All RIWI's products and services continue uninterrupted.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

There is nothing additional to report.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There is nothing to report on these matters.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There is nothing to report on these matters.

8. Describe the acquisition of new customers or loss of customers.

There is nothing additional to report.



9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There is nothing additional to report.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There is nothing additional to report.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including Report on any labour disputes and resolutions of those disputes if applicable.

There is nothing to report on these matters.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There is nothing to report on these matters.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There is nothing to report on these matters.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

RIWI does not have any debt. There is nothing to report on these matters.

16. Provide details of any changes in directors, officers or committee members. There is nothing to report on these matters.



17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

RIWI's technologies and growing computational infrastructure continue to never collect, process, store or transfer personally identifiable data. In EU countries and in the United States, social media firms, digital advertising and other technology and data collection firms face increasing regulatory scrutiny and fines for business practices that rely on collecting, re-publishing, selling, using or putting at risk customers' personal information. RIWI's computational infrastructure enables the Company to deploy different approaches to demonstrate compliance.



Certificate of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof, there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 6, 2020

<u>Neil Seeman</u>

Name of Director or Senior Officer

<u>/s/ Neil Seeman</u>

Signature

Chief Executive Officer

Official Capacity

Issuer Details	For Month End	Date of Report		
Name of Issuer				
RIWI Corp.	March, 2020	2020/04/06		
Issuer Address:				
180 Bloor Street West, Suite 1000				
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.		
Toronto, ON M5S 2V6	N/A	+1-888-505-RIWI (7494)		
Contact Name:	Contact Position:	Contact Telephone No.		
Daniel Im	Chief Financial Officer	647-274-7045		
Contact Email Address:	Web Site Address:			
danielim@riwi.com	https://riwi.com			